Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

Eli Lilly and Company launched its weight loss ... According to the company, the injection is supposed to be taken once every week. One single vial of 2.5 mg will cost Rs. 3500 and one single ...

Lilly beats Novo Nordisk to launch weight-loss ... Mounjaro, a once-weekly injection approved by India's drug regulator, is priced at 4,375 rupees ($50.67) for a 5 mg vial and 3,500 rupees ...

EXCLUSIVE: Tony-nominated Lily Rabe has signed with Gersh for representation in all areas. Rabe is known for her multiple roles in Ryan Murphy’s FX anthology series American Horror Story ...

MNC pharma major Eli Lilly has launched Mounjaro (tirzepatide), a weekly injection for obesity and type 2 diabetes, after obtaining approval from India’s Central Drugs Standard Control ...

Eli Lilly is developing what could be the first oral GLP-1 agonist. Late-stage clinical trial data is coming this year. The stock has a steep valuation despite trading sideways since the summer.

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...

US-based pharmaceutical giant Eli Lilly has launched its diabetes and ... Mounjaro is a once-weekly injection available at the starting dose of 2.5 mg. A single-dose vial of 2.5 mg is priced ...

Showcasing a limited-edition, hand-painted print, the new collection features coordinating styles for kids and adults. By Erin Lassner E-Commerce Writer If you purchase an independently reviewed ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term protection. If this yearly injection is approved and widely implemented ...

Follow Bloomberg India on WhatsApp for exclusive content and analysis on what billionaires, businesses and markets are doing. Sign up here. Eli Lilly and Co. has begun selling its blockbuster ...

Eli Lilly stock has generated fantastic returns for investors over the past five years. The company possesses many lucrative growth opportunities to ensure it remains an excellent buy in the years ...